Jeff Sharman, MD

Jeff Sharman, MD, is an attending physician at the Willamette Valley Cancer Institute and Research Center in Eugene, OR, where he also serves as the medical director of hematology research for The US Oncology Network. He received an undergraduate degree in biochemistry and cellular biology from the University of California, San Diego, followed by his MD degree from the University of California, Davis. He completed his medical residency at Massachusetts General Hospital/Harvard University followed by his fellowship training in both hematology and oncology at Stanford University.

Dr Sharman has been deeply engaged in the clinical development of novel therapeutics within lymphoid malignancies. He was among the first to propose the inhibition of B-cell receptor signaling as a therapeutic strategy within lymphoid malignancies, and he led the initial studies of numerous drugs within the class. He treated the very first patient with chronic lymphocytic leukemia in the world with ibrutinib, and he has contributed to the clinical development of acalabrutinib, zanubrutinib, and pirtobrutinib, among other Bruton tyrosine kinase inhibitors. He also helped lead the development of several phosphoinositide 3-kinase inhibitors, including idelalisib and umbralisib; novel anti-CD20 antibodies, including obinutuzumab and ublituximab; antibody-drug conjugates; BCL-2 antagonists; and immunomodulatory drugs in both chronic lymphocytic leukemia and non-Hodgkin lymphoma. 

He has a busy community oncology–based clinical practice, seeing patients with not only hematologic malignancies but also the full range of solid tumors.